{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:53:37Z","timestamp":1771566817344,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40261-019-00860-y","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T08:03:25Z","timestamp":1570176205000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate"],"prefix":"10.1007","volume":"40","author":[{"given":"Lei","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Yagoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baiyun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"von Moltke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"860_CR1","unstructured":"The global burden of disease: 2004 update. World Health Organization. \nhttp:\/\/www.who.int\/healthinfo\/global_burden_disease\/2004_report_update\/en\/index.html\n\n. Accessed 27 June 2019."},{"key":"860_CR2","volume-title":"Practice guideline for the treatment of patients with bipolar disorder","author":"RMA Hirschfeld","year":"2002","unstructured":"Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. Practice guideline for the treatment of patients with bipolar disorder. 2nd ed. Washington, DC: American Psychiatric Association; 2002.","edition":"2"},{"key":"860_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/0269881109102919","volume":"23","author":"GM Goodwin","year":"2009","unstructured":"Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition\u2014Recommendations from the British Association for Psychopharmacology. J Psychopharmacol (Oxford). 2009;23:346\u201388.","journal-title":"J Psychopharmacol (Oxford)"},{"key":"860_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bdi.12025","volume":"15","author":"LN Yatham","year":"2013","unstructured":"Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15:1\u201344.","journal-title":"Bipolar Disord"},{"key":"860_CR5","first-page":"180","volume":"20","author":"KN Fountoulakis","year":"2017","unstructured":"Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: the clinical guidelines. Int J Neuropsychopharmacol. 2017;20:180\u201395.","journal-title":"Int J Neuropsychopharmacol"},{"key":"860_CR6","unstructured":"Zyprexa [package insert]. Indianapolis: Eli Lilly and Company; 2018."},{"key":"860_CR7","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","volume":"378","author":"A Cipriani","year":"2011","unstructured":"Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378:1306\u201315.","journal-title":"Lancet"},{"key":"860_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1080\/15622975.2017.1384850","volume":"19","author":"H Grunze","year":"2018","unstructured":"Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry. 2018;19:2\u201358.","journal-title":"World J Biol Psychiatry"},{"key":"860_CR9","first-page":"CD004367","volume":"1","author":"A Cipriani","year":"2009","unstructured":"Cipriani A, Rendell JM, Geddes J. Olanzapine in long-term treatment for bipolar disorder. Cochrane Database Syst Rev. 2009;1:CD004367.","journal-title":"Cochrane Database Syst Rev"},{"key":"860_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.schres.2017.10.014","volume":"195","author":"BL Silverman","year":"2018","unstructured":"Silverman BL, Martin W, Memisoglu A, et al. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophr Res. 2018;195:245\u201351.","journal-title":"Schizophr Res"},{"key":"860_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","volume":"176","author":"WF Martin","year":"2019","unstructured":"Martin WF, Correll CU, Weiden PJ, et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019;176:457\u201367.","journal-title":"Am J Psychiatry"},{"key":"860_CR12","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.clinthera.2018.09.002","volume":"40","author":"L Sun","year":"2018","unstructured":"Sun L, McDonnell D, von Moltke L. Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia. Clin Ther. 2018;40:1845\u201354.","journal-title":"Clin Ther"},{"key":"860_CR13","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). E6(R2). Guideline for good clinical practice. European Medicines Agency; 2002. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002874.pdf\n\n. Accessed 27 June 2019."},{"key":"860_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177\u201393.","journal-title":"Clin Pharmacokinet"},{"key":"860_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97\u2013170.","journal-title":"Bipolar Disord"},{"key":"860_CR16","first-page":"81","volume":"25","author":"K Kassahun","year":"1997","unstructured":"Kassahun K, Mattiuz E, Nyhart E Jr, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997;25:81\u201393.","journal-title":"Drug Metab Dispos"},{"key":"860_CR17","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1124\/dmd.115.064790","volume":"43","author":"P Korprasertthaworn","year":"2015","unstructured":"Korprasertthaworn P, Polasek TM, Sorich MJ, et al. In vitro characterization of the human liver microsomal kinetics and reaction phenotyping of olanzapine metabolism. Drug Metab Dispos. 2015;43:1806\u201314.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"860_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40261-019-00775-8","volume":"39","author":"L Sun","year":"2019","unstructured":"Sun L, McDonnell D, Yu M, Kumar V, von Moltke L. A phase I open-label study to evaluate the effects of rifampin on the pharmacokinetics of olanzapine and samidorphan administered in combination in healthy human subjects. Clin Drug Investig. 2019;39(5):477\u201384.","journal-title":"Clin Drug Investig"},{"key":"860_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1023\/A:1006990925122","volume":"19","author":"TA Ketter","year":"1999","unstructured":"Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol. 1999;19:511\u201332.","journal-title":"Cell Mol Neurobiol"},{"key":"860_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/dmd.108.022426","volume":"37","author":"UA Argikar","year":"2009","unstructured":"Argikar UA, Remmel RP. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009;37:229\u201336.","journal-title":"Drug Metab Dispos"},{"key":"860_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.phrs.2016.02.014","volume":"106","author":"E Spina","year":"2016","unstructured":"Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72\u201386.","journal-title":"Pharmacol Res"},{"key":"860_CR22","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","volume":"64","author":"C Zhang","year":"2012","unstructured":"Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev. 2012;64:930\u201342.","journal-title":"Adv Drug Deliv Rev"},{"key":"860_CR23","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/JCP.0000000000000601","volume":"36","author":"G Schoretsanitis","year":"2016","unstructured":"Schoretsanitis G, Haen E, Grunder G, et al. Pharmacokinetic drug-drug interactions of mood stabilizers and risperidone in patients under combined treatment. J Clin Psychopharmacol. 2016;36:554\u201361.","journal-title":"J Clin Psychopharmacol"},{"key":"860_CR24","first-page":"658","volume":"276","author":"BJ Ring","year":"1996","unstructured":"Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther. 1996;276:658\u201366.","journal-title":"J Pharmacol Exp Ther"},{"key":"860_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/j.1552-4604.1994.tb01994.x","volume":"34","author":"ME Ward","year":"1994","unstructured":"Ward ME, Musa MN, Bailey L. Clinical pharmacokinetics of lithium. J Clin Pharmacol. 1994;34:280\u20135.","journal-title":"J Clin Pharmacol"},{"key":"860_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","volume":"61","author":"N Bhana","year":"2001","unstructured":"Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61:111\u201361.","journal-title":"Drugs"},{"key":"860_CR27","unstructured":"Lithium [package insert]. Columbus: Roxane Laboratories, Inc.; 2016."},{"key":"860_CR28","unstructured":"Depakote [package insert]. North Chicago: AbbVie Inc.; 2017."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00860-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00860-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00860-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T23:56:56Z","timestamp":1601683016000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00860-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["860"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00860-y","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]},"assertion":[{"value":"4 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was sponsored by Alkermes, Inc., which is a pharmaceutical company developing OLZ\/SAM, a combination product of olanzapine and samidorphan for the treatment of schizophrenia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lei Sun, Sergey Yagoda, Baiyun Yao, Christine Graham, and Lisa von Moltke are employees of Alkermes, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was designed and carried out in accordance with the principles of Good Clinical Practice that have their origin in the Declaration of Helsinki and its amendments and in accordance with local regulations and International Conference on Harmonisation guidelines. The study protocol and informed consent forms were approved by the clinical site\u2019s institutional review board prior to any subjects being enrolled into the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects provided written informed consent before participating in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}